



ARV Therapies and Therapeutic Strategies  
REPORTING ON EACS 2015  
**Comprehensive Expert Review  
and Discussion of Key Presentations**

An Independent CME Activity Jointly Provided by Postgraduate Institute for Medicine and ViralEd, Inc.  
The coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.

**Dolutegravir Monotherapy in HIV-infected Patients  
with Sustained Viral Suppression: A 24-week Pilot Study**

J. Rojas, J.L. Blanco, M. Lonca, B. Torres, M. Parera, A. Gonzalez, J. Mallolas,  
A. Tricas, L. Moreno, F. Garcia, J.M. Gatell, E. Martinez

Abstract LBPS4/2

**Dolutegravir Monotherapy in HIV-infected Patients with Sustained Viral  
Suppression: Design and Baseline Characteristics**

- 33 Virally suppressed patients switched to DTG 50mg QD for adverse effects, comorbidities, interactions, archived resistance

<b>Age</b>	56 (50-62)
<b>Women</b>	18 (55%)
<b>Years Since HIV Diagnosis</b>	19 (17-23)
<b>AIDS-Defining Events</b>	13 (39%)
<b>Years with VL Below Detection Threshold</b>	8 (4-13)
<b>CD4 Cells (/mm<sup>3</sup>)</b>	596 (420-843)
<b>CD8 Cells (/mm<sup>3</sup>)</b>	990 (624-1288)
<b>CD4/CD8 Ratio</b>	0.64 (0.46-1.01)
<b>PI/r-Based</b>	22 (67%)
<b>NNRTI-Based</b>	<b>9 (27%)</b>
<b>INSTI-Based</b>	<b>2 (6%)</b>

## Martinez E, et al: Virological Response and Other Outcomes

- At 24 weeks, the therapeutic efficacy of dolutegravir monotherapy was 97% (95% CI 83%-100%) (ITT non-completer=failure)
- One patient had low-level virological failure after 4 weeks (88 copies/mL, and confirmed as 155 copies/mL). Previous VF to a RAL-containing regimen without IN-GRT by the time of this VF
- HIV DNA genotypic resistance tests detected no integrase mutations at 4 weeks, but 118R was detected in 7% of the integrated-DNA in PMBC at 24 weeks
- There was a positive impact (interactions, improvement of GI symptoms, lipids, Framingham score) on several of the reasons that motivated switching to DTG monotherapy

Martinez E, et al. 15th EACS, Barcelona, Spain, October 21-24, 2015; Abst. LBPS4/2.

## ARV Therapies and Therapeutic Strategies

REPORTING ON EACS 2015

### *Comprehensive Expert Review and Discussion of Key Presentations*

An Independent CME Activity Jointly Provided by Postgraduate Institute for Medicine and ViralEd, Inc.  
The coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.

## Dolutegravir Monotherapy in HIV-infected Patients with Suppressed HIV Viremia

C. Katlama, C. Soulié, C. Blanc, A. Denis, F. Caby, L. Schneider, M.A. Valantn,  
R. Tubiana, M. Kirstetter, E. Valdenassi, G. Peytavin, V. Calvez, A.G. Marcelin


Abstract PS4/4

## Dolutegravir Monotherapy in HIV-infected Patients with Suppressed HIV Viremia: Design and Baseline Characteristics

HIV RNA <50 cp/mL  
on ART  
Switch to Mono DTG 50mg QD

May 14 to Jan 15

28 Patients Enrolled




- 28 Patients
- Age: 48 Years
- ART Duration: 17 Years [11-20]
- Viral Suppression: 6.6 Years [3.5-7.9]
- CD4 T Cells: 624/mm<sup>3</sup> [524-761]
- CD4 T Cells Nadir: 215/mm<sup>3</sup> [110-279]
- DNA: 195 cp/106PBMC [94-641]
- Baseline ART
 

• Triple Drug ART	10 (36%)
• Dual ART	9 (32%)
• Mono ART (DRV/r)	9 (32%)
• INI Containing Regimen	7 (25%)

Katlama C, et al. 15th EACS, Barcelona, Spain, October 21-24, 2015; Abstr. PS4/4.


## Katlama C, et al: Results

- 28 Pts
- 25/28 VL<50 cp/mL
  - All <50 cp/mL
  - All <20 cp/mL except 37 cp/mL (1)
  - 1 blip W4 (52 cp/mL)
- 3 Virological Failures
  - W12: 1 pt
    - VL 138/469 cp/mL
  - W24: 2 pts
    - VL: 2220 cp/mL
    - VL: 291 cp/mL



Katlama C, et al. 15th EACS, Barcelona, Spain, October 21-24, 2015; Abstr. PS4/4.

# Katlama C, et al: Virological Failures



Prior INI : ETV+ RAL 8 Months  
Stop for Pregnancy No Blip

ART : TDF/FTC/EVG No Blip

ART TDF/TC/RAL (Blip 37cp)

Katlama C, et al. 15th EACS, Barcelona, Spain, October 21-24, 2015; Abst. PS4/4.